62P Predictive value of combined positive score (CPS) and tumor proportion score (TPS) for immunotherapy response in advanced non-small cell lung cancer (NSCLC)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?

“…Other studies have explored the predictive value of tumor-infiltrating lymphocytes in tumor biopsies for survival outcomes ( 5 ). Additionally, the scoring of PD-L1 on inflammatory immune cells, in addition to tumor cells alone, may provide useful information for predicting treatment response ( 6 ). Baseline immune cell presence, whether detected in peripheral blood or tumor biopsies, appears to play a critical role in determining the likelihood of response to immunotherapy treatment and should therefore be considered in future large-scale phase 3 trials.…”